EA200501104A1 - Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция - Google Patents

Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция

Info

Publication number
EA200501104A1
EA200501104A1 EA200501104A EA200501104A EA200501104A1 EA 200501104 A1 EA200501104 A1 EA 200501104A1 EA 200501104 A EA200501104 A EA 200501104A EA 200501104 A EA200501104 A EA 200501104A EA 200501104 A1 EA200501104 A1 EA 200501104A1
Authority
EA
Eurasian Patent Office
Prior art keywords
formula
halogen
case
nhc
group
Prior art date
Application number
EA200501104A
Other languages
English (en)
Other versions
EA008539B1 (ru
Inventor
Леена Отсомаа
Туула Коскелайнен
Арто Карьялайнен
Сирпа Раску
Пьеро Поллеселло
Йоуко Левийоки
Original Assignee
Орион Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8565286&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA200501104(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Орион Корпорейшн filed Critical Орион Корпорейшн
Publication of EA200501104A1 publication Critical patent/EA200501104A1/ru
Publication of EA008539B1 publication Critical patent/EA008539B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Терапевтически активные соединения формулы (I) или (II)где X представляет -O-, -CH- или -C(O)-; Z представляет -CHR- или валентную связь; Y представляет -CH-, -C(O)-, CH(OR)-, -O-, -S-; при условии, что в случае, когда Z является валентной связью, Y не является C(O); пунктирная линия представляет необязательную двойную связь, в этом случае Z является -CR-, а Y представляет -CH-, -C(O)- или CH(OR)- (в формуле II) или -CH- (в формуле I); Rи Rнезависимо представляют H, низший алкил, низший алкокси, -NO, галоген, -CF, -OH, бензилокси или группу формулы (IIIa); Rпредставляет H, CN, галоген, -CONH, -COOR, -CHNRR, NHC(O)R, NHCHR, NHR, NRR, NHC(NH)NHCHили, в случае, когда соединение представлено формулой (II), где существует необязательная двойная связь, или в случае, когда Rили Rявляется бензилокси или группой формулы (IIIa), или в случае, когда пиридиновое кольцо в формуле (I) или (II) связано с атомом кислорода в 3-, 4- или 5-положении, Rможет также представлять собой -NOили NRR; Rпредставляет H, -NO, CN, галоген, -CONH, -COOR, -CHNRR, -NRR, -NHC(O)Rили -NHC(NH)NHCH; Rпредставляет алкил, замещенный 1-3 заместителями, выбранными из группы, состоящей из галогена, амино и гидрокси, или карбоксиалкил, в котором алкильная часть является необязательно замещенной 1-3 заместителями, выбранными из группы, состоящей из галогена, амино и гидроксила, -CHRNRR, или одну из следующих групп: формулы (IVa), (IVb), (IVc), (IVd), (IVe), и их фармацевтически приемлемые соли и сложные эфиры. Данные соединения являются сильными ингибиторами механизма обмена Na/Ca.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200501104A 2003-01-09 2004-01-09 Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция EA008539B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI20030030A FI20030030A0 (fi) 2003-01-09 2003-01-09 Uusia yhdisteitä
PCT/FI2004/000011 WO2004063191A1 (en) 2003-01-09 2004-01-09 Pyridine derivatives useful for inhibiting sodium/calcium exchange system

Publications (2)

Publication Number Publication Date
EA200501104A1 true EA200501104A1 (ru) 2005-12-29
EA008539B1 EA008539B1 (ru) 2007-06-29

Family

ID=8565286

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200501104A EA008539B1 (ru) 2003-01-09 2004-01-09 Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция

Country Status (22)

Country Link
US (1) US7482340B2 (ru)
EP (1) EP1583759A1 (ru)
JP (1) JP2006516271A (ru)
KR (1) KR20050095601A (ru)
CN (1) CN100457752C (ru)
AR (1) AR042733A1 (ru)
AU (1) AU2004203943B2 (ru)
BR (1) BRPI0406669A (ru)
CA (1) CA2512184A1 (ru)
EA (1) EA008539B1 (ru)
FI (1) FI20030030A0 (ru)
HR (1) HRP20050703A2 (ru)
IL (1) IL169435A0 (ru)
IS (1) IS7969A (ru)
MX (1) MXPA05007435A (ru)
NO (1) NO20053730L (ru)
NZ (1) NZ541087A (ru)
PL (1) PL378326A1 (ru)
RS (1) RS20050528A (ru)
UA (1) UA81941C2 (ru)
WO (1) WO2004063191A1 (ru)
ZA (1) ZA200505461B (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011507A0 (fi) * 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä
KR101233223B1 (ko) * 2004-12-21 2013-02-14 제이엔씨 석유 화학 주식회사 크로만환을 가지는 액정 화합물, 액정 조성물 및 이 액정조성물을 함유하는 액정 표시소자
MX2009008798A (es) * 2007-02-22 2009-08-24 Syngenta Participations Ag Derivados de iminipiridina y sus usos como microbicidas.
AU2011340258C1 (en) * 2010-12-06 2016-10-20 Autifony Therapeutics Limited Hydantoin derivatives useful as Kv3 inhibitors
EP2524908A1 (en) * 2011-05-20 2012-11-21 LEK Pharmaceuticals d.d. Process for the preparation of alfa-substituted ketones and their application in synthesis of pharmaceutically active compounds
US8912224B2 (en) 2011-09-12 2014-12-16 Sanofi Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
KR101817925B1 (ko) 2011-09-12 2018-01-12 사노피 치환된 ２-（크로만-６-일옥시）-티아졸 및 약제로서의 이의 용도
JP5941637B2 (ja) * 2011-09-12 2016-06-29 サノフイ 置換２−（クロマン−６−イルオキシ）−チアゾール及び医薬としてのその使用
SI2567958T1 (sl) 2011-09-12 2015-01-30 Sanofi Substituirani 2-(kroman-6-iloksi)-tiazoli in njihova uporaba kot farmacevtiki
WO2013144191A1 (de) * 2012-03-29 2013-10-03 Bayer Intellectual Property Gmbh Substituierte 2 -amino - 3 - cyanopyridine als inhibitoren des natrium calcium austausches und ihre verwendung bei kardiovaskulären erkrankungen
TWI633095B (zh) 2013-03-08 2018-08-21 賽諾菲公司 經取代－６－基氧基－環烷類及其作為醫藥品之用途
GB201416186D0 (en) 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
WO2016144702A1 (en) 2015-03-06 2016-09-15 Pharmakea, Inc. Lysyl oxidase-like 2 inhibitors and uses thereof
EA034891B1 (ru) 2015-03-06 2020-04-02 Фармакеа, Инк. Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение
CN108137807B (zh) * 2015-08-19 2020-09-29 日产化学工业株式会社 液晶取向剂中使用的酰亚胺系聚合物
US10774069B2 (en) 2016-09-07 2020-09-15 Pharmakea, Inc. Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making
JP7097874B2 (ja) 2016-09-07 2022-07-08 ファーマケア，インク． リシルオキシダーゼ様２阻害剤の使用
WO2019175464A1 (en) 2018-03-14 2019-09-19 Orion Corporation Compounds useful as inhibitors of sodium-calcium exchanger (ncx)
KR20230058399A (ko) 2020-07-28 2023-05-03 재즈 파마슈티칼즈 아일랜드 리미티드 융합된 바이사이클릭 raf 억제제 및 이의 사용 방법
CN115850258A (zh) * 2022-12-27 2023-03-28 东北林业大学 一种马赛替尼的合成方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2820817A (en) 1954-02-04 1958-01-21 Mcneilab Inc Oxygenated indan compounds and method of making the same
US3862232A (en) 1963-07-03 1975-01-21 Upjohn Co 1-(p-hydroxyphenyl)-2-phenyl-6-(2-diethylaminoethoxy)-3,4-dihydronaphthalene and the salts thereof
BE650081A (ru) 1963-07-03
GB1154119A (en) 1968-05-20 1969-06-04 Merck Ag E 3-Alkyl-Flavanones
JPH04113839A (ja) * 1990-09-05 1992-04-15 Mitsubishi Petrochem Co Ltd ポリカーボネート樹脂積層物
FR2733685B1 (fr) 1995-05-05 1997-05-30 Adir Utilisation des derives du benzopyrane pour l'obtention de compositions pharmaceutiques destinees au traitement des pathologies liees a l'echangeur c1-/hc03-, na+ independant
JPH0967336A (ja) 1995-09-04 1997-03-11 Kanebo Ltd 新規なイソチオウレア誘導体
DE69810606T2 (de) 1997-03-27 2003-10-09 Taisho Pharmaceutical Co Ltd 2-phenoxyanilinderivate
JPH1149752A (ja) 1997-08-05 1999-02-23 Taisho Pharmaceut Co Ltd フェノキシピリジン誘導体
DE19742508A1 (de) * 1997-09-26 1999-04-01 Hoechst Marion Roussel De Gmbh Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltende pharmazeutische Zubereitungen
ES2191341T3 (es) 1997-10-20 2003-09-01 Taisho Pharmaceutical Co Ltd Derivados de la 2-fenoxianilina.
JPH11302235A (ja) 1998-04-15 1999-11-02 Taisho Pharmaceut Co Ltd フェノキシアルキルアミン誘導体
JP2002542291A (ja) 1999-04-23 2002-12-10 ブリストル−マイヤーズ スクイブ カンパニー ジ環式アシルグアニジン・ナトリウム／プロトン交換抑制剤および方法
WO2001021610A1 (en) * 1999-09-17 2001-03-29 Nissan Chemical Industries, Ltd. Benzopyran derivative
FI20011507A0 (fi) * 2001-07-10 2001-07-10 Orion Corp Uusia yhdisteitä

Also Published As

Publication number Publication date
AR042733A1 (es) 2005-06-29
NZ541087A (en) 2008-04-30
EP1583759A1 (en) 2005-10-12
HRP20050703A2 (en) 2005-10-31
JP2006516271A (ja) 2006-06-29
ZA200505461B (en) 2006-03-29
US7482340B2 (en) 2009-01-27
CA2512184A1 (en) 2004-07-29
WO2004063191A1 (en) 2004-07-29
KR20050095601A (ko) 2005-09-29
NO20053730L (no) 2005-10-07
MXPA05007435A (es) 2005-09-12
CN1745078A (zh) 2006-03-08
IL169435A0 (en) 2007-07-04
EA008539B1 (ru) 2007-06-29
UA81941C2 (ru) 2008-02-25
AU2004203943B2 (en) 2009-09-17
IS7969A (is) 2005-08-02
NO20053730D0 (no) 2005-08-03
AU2004203943A1 (en) 2004-07-29
PL378326A1 (pl) 2006-03-20
US20060241147A1 (en) 2006-10-26
FI20030030A0 (fi) 2003-01-09
CN100457752C (zh) 2009-02-04
RS20050528A (en) 2007-06-04
BRPI0406669A (pt) 2005-12-20

Similar Documents

Publication Publication Date Title
EA200501104A1 (ru) Производные пиридина, пригодные для ингибирования системы обмена натрия/кальция
DE69512797D1 (en) Prostaglandin-synthase hemmer
EP0353955A3 (en) Novel compounds
ES495412A0 (es) Procedimiento para la preparacion de derivados de n-fe- noxialcohilpiperidina
EP0313289A3 (en) Process for the preparation of purine compounds and intermediates therefor
EP0351385A3 (en) New amidino and guanidino derivatives
SE8102220L (sv) Anvendning av substituerade derivat av 4-fenyl-4-oxo-2-butensyra sasom lekemedel
EA200400161A1 (ru) Новые соединения, являющиеся сильнодействующими ингибиторами механизма обмена ионов na+/ca2+ при лечении аритмии
ES8603406A1 (es) Un procedimiento para producir derivados de acilindol
NO166321C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive pyridinforbindelser.
ATE20066T1 (de) Neue basisch substituierte 4-phenyl-4,5,6,7tetrahydrothieno-(2,3-c)pyridine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen.
DK0944618T3 (da) Nye N-benzensulfonyl-L-prolin-derivater, fremgangsmåde til deres fremstilling og deres anvendelse til terapeutiske formål
DK12584A (da) Bicyclo(4.2.0)1,3,5-octatrienderivater, fremgangsmaade til deres fremstilling og farmaceutiske kompositioner indeholdende disse
NO985186D0 (no) Forbindelser med camptothecin-grunnstruktur, isolert fra Mappia foetida, og anvendelse derav som syntoner for nye legemidler samt som terapeutiske midler
PT99280A (pt) Processo de preparacao de derivados do indolo e de composicoes farmaceuticas
EA200100344A2 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
DK0660840T3 (da) Phosphono-substituerede tetrazolderivater.
ES543783A0 (es) Procedimiento de preparacion de un derivado 1,1-difenilpro- pan-1-ol
SE8405332L (sv) 2h-azeto (2,1-a)-isokinolinderivat, forfarande for deras framstellning och farmaceutiska kompositioner innehallande dem
HU894471D0 (en) Process for the preparation of 15-amino-20,21-dinor-eburnamenine derivatives and pharmaceutical compositions containing them
ES8506014A1 (es) Procedimiento para la preparacion de derivados de acridanona.
ES8304576A1 (es) "procedimiento para la preparacion de nuevas cefalosporinas".
DE69610477T2 (de) 5H- THIAZOLO(3,2-a)PYRIMIDIN-5-ON-DERIVATE

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU